CL2019001008A1 - Formas cristalinas de 4–(2–((1r,2r)–2–hidroxiciclohexilamino) benzotiazol–6–iloxi)–n–metilpicolinamida. - Google Patents
Formas cristalinas de 4–(2–((1r,2r)–2–hidroxiciclohexilamino) benzotiazol–6–iloxi)–n–metilpicolinamida.Info
- Publication number
- CL2019001008A1 CL2019001008A1 CL2019001008A CL2019001008A CL2019001008A1 CL 2019001008 A1 CL2019001008 A1 CL 2019001008A1 CL 2019001008 A CL2019001008 A CL 2019001008A CL 2019001008 A CL2019001008 A CL 2019001008A CL 2019001008 A1 CL2019001008 A1 CL 2019001008A1
- Authority
- CL
- Chile
- Prior art keywords
- crystalline forms
- hydroxycyclohexylamino
- methylpicolinamide
- benzothiazol
- yloxy
- Prior art date
Links
- -1 benzothiazol-6-yloxy Chemical group 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408358P | 2016-10-14 | 2016-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001008A1 true CL2019001008A1 (es) | 2019-06-21 |
Family
ID=60320932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001008A CL2019001008A1 (es) | 2016-10-14 | 2019-04-12 | Formas cristalinas de 4–(2–((1r,2r)–2–hidroxiciclohexilamino) benzotiazol–6–iloxi)–n–metilpicolinamida. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10934273B2 (enExample) |
| EP (1) | EP3526217B1 (enExample) |
| JP (1) | JP7068288B2 (enExample) |
| KR (1) | KR20190064589A (enExample) |
| CN (1) | CN109843880B (enExample) |
| AU (1) | AU2017342239B2 (enExample) |
| BR (1) | BR112019006914A2 (enExample) |
| CA (1) | CA3039764A1 (enExample) |
| CL (1) | CL2019001008A1 (enExample) |
| ES (1) | ES2949414T3 (enExample) |
| IL (1) | IL265893A (enExample) |
| MX (1) | MX2019004345A (enExample) |
| RU (1) | RU2019114208A (enExample) |
| WO (1) | WO2018069892A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
| KR20220130698A (ko) * | 2019-12-20 | 2022-09-27 | 에피자임, 인코포레이티드 | Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101432281B (zh) * | 2006-04-19 | 2013-08-28 | 诺瓦提斯公司 | 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法 |
| KR101464385B1 (ko) * | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법 |
| SI2704713T1 (sl) * | 2011-05-05 | 2017-05-31 | Novartis Ag | CSF-1R inhibitorji za zdravljenje možganskih tumorjev |
| EP3233918A1 (en) * | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
-
2017
- 2017-10-13 CN CN201780063254.XA patent/CN109843880B/zh active Active
- 2017-10-13 WO PCT/IB2017/056379 patent/WO2018069892A1/en not_active Ceased
- 2017-10-13 US US16/341,124 patent/US10934273B2/en active Active
- 2017-10-13 EP EP17797745.1A patent/EP3526217B1/en active Active
- 2017-10-13 AU AU2017342239A patent/AU2017342239B2/en not_active Ceased
- 2017-10-13 BR BR112019006914A patent/BR112019006914A2/pt not_active IP Right Cessation
- 2017-10-13 JP JP2019520040A patent/JP7068288B2/ja not_active Expired - Fee Related
- 2017-10-13 RU RU2019114208A patent/RU2019114208A/ru not_active Application Discontinuation
- 2017-10-13 ES ES17797745T patent/ES2949414T3/es active Active
- 2017-10-13 KR KR1020197010527A patent/KR20190064589A/ko not_active Ceased
- 2017-10-13 MX MX2019004345A patent/MX2019004345A/es unknown
- 2017-10-13 CA CA3039764A patent/CA3039764A1/en not_active Abandoned
-
2019
- 2019-04-07 IL IL265893A patent/IL265893A/en unknown
- 2019-04-12 CL CL2019001008A patent/CL2019001008A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017342239A1 (en) | 2019-04-18 |
| EP3526217A1 (en) | 2019-08-21 |
| ES2949414T3 (es) | 2023-09-28 |
| AU2017342239B2 (en) | 2020-05-28 |
| CA3039764A1 (en) | 2018-04-19 |
| WO2018069892A1 (en) | 2018-04-19 |
| JP2019530719A (ja) | 2019-10-24 |
| BR112019006914A2 (pt) | 2019-07-02 |
| CN109843880B (zh) | 2023-12-01 |
| KR20190064589A (ko) | 2019-06-10 |
| US10934273B2 (en) | 2021-03-02 |
| JP7068288B2 (ja) | 2022-05-16 |
| RU2019114208A (ru) | 2020-11-16 |
| IL265893A (en) | 2019-06-30 |
| EP3526217B1 (en) | 2023-04-19 |
| RU2019114208A3 (enExample) | 2020-11-18 |
| US20200190057A1 (en) | 2020-06-18 |
| MX2019004345A (es) | 2019-07-01 |
| CN109843880A (zh) | 2019-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
| CO2017004782A2 (es) | Conjugados de anticuerpo- farmaco | |
| CL2018000376A1 (es) | Derivados heterobicíclicos microbicidas. | |
| MX2019014514A (es) | Compuestos para tratar la enfermedad de huntington. | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| MX2018004515A (es) | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. | |
| CR20160456A (es) | Compuestos de heteroarilo o arilo bibíclicos fusionados | |
| MX2019015888A (es) | Bifenil amidas con grupos eter modificados como inhibidores de hsp90 e inductores de hsp70. | |
| BR112015030011A2 (pt) | composições e métodos para intensificar a germinação | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| IL248038A0 (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| CL2019003670A1 (es) | Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta. | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| MX2019003945A (es) | Formas cristalinas y salinas de compuestos agonistas de ppar. | |
| DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
| EP3648739A4 (en) | COMPOSITION FOR INJECTION | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| EP3624839A4 (en) | DOSING PLANS FOR ANTI-CD33 IMMUNE CONJUGATES | |
| UY36261A (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| EP3458432A4 (en) | FERTILIZER COMPOSITION | |
| MX375918B (es) | Composiciones para el tratamiento de la fibrosis y afecciones relacionadas con la fibrosis. | |
| CO2017007940A2 (es) | Péptidos antagonistas prgc | |
| CL2016003230A1 (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas |